# Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

> **NCT05265650** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** BO-112 in combination with ablative radiotherapy (SABR) and nivolumab
- **PROCEDURE:** Tissue Biopsies

## Key facts

- **NCT ID:** NCT05265650
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-13
- **Primary completion:** 2024-03
- **Final completion:** 2024-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265650, "Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05265650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*